Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor

Supportive Care in Cancer

Volumn 24, Issue 6, 2016, Pages 2677-2684

  Pettengell, Ruth ^a   Bias, Peter ^b   Mueller, Udo ^b   Lang, Nicole ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Teva Ratiopharm   (Germany)

Author keywords

Adverse drug event; Drug toxicity; Filgrastim; Granulocyte colony stimulating factor; Neutropenia; Safety

Indexed keywords

DOCETAXEL; DOXORUBICIN; FILGRASTIM; PLACEBO; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; HEMATOLOGIC AGENT;

ABDOMINAL PAIN; ALLERGIC REACTION; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HEADACHE; HUMAN; HYPERSENSITIVITY; IMMUNOGENICITY; INJECTION SITE REACTION; JAW PAIN; LUNG CANCER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PELVIC PAIN; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PRURITUS; RASH; RESPIRATORY DISTRESS SYNDROME; SKIN ALLERGY; SPLENOMEGALY; UPPER ABDOMINAL PAIN; URTICARIA; ADULT; CHEMICALLY INDUCED; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; MALE; META ANALYSIS; NEOPLASMS;

ADULT; ANTINEOPLASTIC AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC AGENTS; HUMANS; MALE; NEOPLASMS; NEUTROPENIA;

EID: 84954449240     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-015-3057-2     Document Type: Article

References (28)

1. Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100:228–237. doi:10.1002/cncr.11882
2. Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340
3. Gabrilove JL, Jakubowski A, Scher H, et al. (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414–1422. doi:10.1056/NEJM198806023182202
4. Morstyn G, Campbell L, Lieschke G, et al. (1989) Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol 7:1554–1562
5. Crawford J, Ozer H, Stoller R, et al. (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164–170. doi:10.1056/NEJM199107183250305
6. Trillet-Lenoir V, Green J, Manegold C, et al. (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319–324
7. Gatzemeier U, Ciuleanu T, Dediu M, Ganea-Motan E, Lubenau H, del Giglio A (2009) XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol 4:736–740. doi:10.1097/JTO.0b013e3181a52964
8. Engert A, Griskevicius L, Zyuzgin Y, Lubenau H, del Giglio A (2009) XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma 50:374–379. doi:10.1080/10428190902756081
9. del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H (2008) XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer 8:332–338. doi:10.1186/1471-2407-8-332
10. Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158–3167. doi:10.1200/JCO.2006.08.8823
11. Smith TJ, Khatcheressian J, Lyman GH, et al. (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205. doi:10.1200/JCO.2006.06.4451
12. Crawford J, Althaus B, Armitage J, et al. (2007) Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 5:188–202
13. Aapro MS, Bohlius J, Cameron DA, et al. (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8–32. doi:10.1016/j.ejca.2010.10.013
14. Crawford J, Caserta C, Roila F (2010) Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 21(suppl 5):v248–v251. doi:10.1093/annonc/mdq195
15. Kouroukis CT, Chia S, Verma S, et al. (2008) Canadian supportive care recommendations for the management of neutropenia in patients with cancer. Curr Oncol 15:9–23
16. Granix [package insert]. (2013) Teva Pharmaceuticals USA, Inc., North Wales, PA.
17. Abraham I, Tharmarajah S, MacDonald K (2013) Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors. Expert Opin Drug Saf 12:235–246. doi:10.1517/14740338.2013.770472
18. A study to evaluate 5 μg/kg tbo-filgrastim in infants, children and adolescents with solid tumors without bone marrow involvement. NCT02190721. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02190721. Accessed 2 November 2015.
19. Nuamah NM, Goker H, Kilic YA, Dagmoura H, Cakmak A (2006) Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (G-CSF). A case report and review of the literature. Haematologica 91:ECR08
20. Stroncek D, Shawker T, Follmann D, Leitman SF (2003) G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion 43:609–613
21. Masood N, Shaikh AJ, Memon WA, Idress R (2008) Splenic rupture, secondary to G-CSF use for chemotherapy induced neutropenia: a case report and review of literature. Cases J 1:418. doi:10.1186/1757-1626-1-418
22. Watring NJ, Wagner TW, Stark JJ (2007) Spontaneous splenic rupture secondary to pegfilgrastim to prevent neutropenia in a patient with non-small-cell lung carcinoma. Am J Emerg Med 25:247–248. doi:10.1016/j.ajem.2006.10.005
23. Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL (2007) Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 40:185–192. doi:10.1038/sj.bmt.1705722
24. Neupogen [package insert]. (2013) Amgen Inc., Thousand Oaks, CA.
25. EMA-Guideline on good pharmacovigilance practice (GVP). Module VII—periodic safety update report (Rev1) (2015) European Medicines Agency Science Medicines Health. www.ema.europa.eu. Accessed 2 November 2015.
26. Martino M, Console G, Irrera G, et al. (2005) Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim. J Clin Apher 20:129–136. doi:10.1002/jca.20049
27. Beelen DW, Ottinger H, Kolbe K, et al. (2002) Filgrastim mobilization and collection of allogeneic blood progenitor cells from adult family donors: first interim report of a prospective German multicenter study. Ann Hematol 81:701–709. doi:10.1007/s00277-002-0553-5
28. Anderlini P, Donato M, Chan KW, et al. (1999) Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion 39:555–560